ESPE2021 ePoster Category 2 Sex differentiation, gonads and gynaecology or sex endocrinology (52 abstracts)
Objective: To study the impact of dual therapy on BMD and Inhibin B in a group of transsexual male adolescents who initiate treatment with advanced pubertal development.
Patients and methodology: Retrospective study of 16 male minors who initiated treatment (Triptorelin and later Testosterone) with complete pubertal development. Variables included: age, weight and height at baseline and at the last visit (calculated in SDS for assigned age and sex), BMD in L1L4 and total body (GE HealthCare’s LUNAR Densitometer: in g/cm2 and calculated in SDS for assigned age and sex), vitamin D and Inhibin B (Enzyme Immunoassay, normal range 25-325 pg/ml) as a marker of ovarian reserve. Statistical analysis with SPSS V25 software.
Results: Initial data: age 13.6±1.6 years, weight-SDS 0.96±1.7, height-SDS 0.1±1.4, BMD L1L4 1.12±0.18 g/cm2 (SDS 0.5±1.3), BMD total body 1.06±0.08 g/cm2 (SDS 0.84±1.03), Inhibin B 32.6±37.5 pg/ml. The determinations were repeated after 14±6 months of Triptorelin therapy (dose 60 µg/kg/4 weeks) and 13.2±8 months, after associating Testosterone (mean dose 113±52 mg/4 weeks). The results are shown in the table. BMD values are normal at baseline and during therapy. BMD-SDS decrease progressively throughout the treatment. The mean initial level of Inhibin B is normal, seems to decrease during Triptorelin therapy and to normalize when Testosterone is associated, (differences are not statistically significant). Vitamin D levels remain low despite replacement therapy. Weight-SDS in the last visit is, on average, in the limits of overweight.
|BMD L1L4 (g/cm2)||1.12±0.18||1.14±0.16||1.12±0.14||ns|
|BMD L1L4 (SDS)||0.5±1.3||0.26±1.5||- 0.37±0.94||0.002|
|BMD total body (g/cm2)||1.06±0.08||1.02±0.09||1.05±0.08||ns|
|BMD total body (SDS)||0.84±1.03||0.66±1.08||0.33±1.04||0.006|
|Inhibin B (pg/ml)||32.6±37.5||14.4±15.7||31.0±29.2||ns|
|Vitamin D (ng/ml)||18.2±7.1||21.1±6.1||ns|
Conclusions: The physiological increase in BMD (g/cm2) at this age it´s not observed but a significant decrease doesn´t appear. Inhibin B doesn´t undergo relevant modifications. Long-term studies are required to ensure the safety of dual therapy.
22 Sep 2021 - 26 Sep 2021